We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
- Authors
Wijermans, P; Lübbert, M; Verhoef, G; Bosly, A; Ravoet, C; Andre, M; Ferrant, A
- Abstract
5-Aza-2'-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that has shown a 50% response rate in a small phase II study in elderly patients with high-risk myelodysplastic syndrome. We performed a second, multicenter phase II study in a larger group of patients to confirm our findings and to study the toxicity of DAC.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Vol 18, Issue 5, p956
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2000.18.5.956